Jacob Soumerai, MD, Massachusetts General Hospital, Boston, MA, compares the safety profiles of current and emerging Bruton’s tyrosine kinase inhibitors (BTKi). Dr Soumerai highlights the ELEVATE CLL RR (NCT02477696) and ALPINE (NCT03734016) trials, which compared the first-generation BTKi ibrutinib to acalabrutinib and zanubrutinib, respectively, in the treatment of chronic lymphocytic leukemia (CLL). Zanubrutinib was also compared to ibrutinib for the treatment of Waldenström’s macroglobulinemia (WM) in the ASPEN trial (NCT03053440). Next-generation BTKi are well tolerated and associated with fewer cardiac adverse events than ibrutinib. Dr Soumerai also comments on the non-covalent BTKi pirtobrutinib, which has been demonstrated as highly active with a favorable safety profile. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyrig